Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

214 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction - Results from the EMPULSE trial.
Tromp J, Kosiborod MN, Angermann CE, Collins SP, Teerlink JR, Ponikowski P, Biegus J, Ferreira JP, Nassif ME, Psotka MA, Brueckmann M, Blatchford JP, Steubl D, Voors AA. Tromp J, et al. Among authors: brueckmann m. Eur J Heart Fail. 2024 Apr;26(4):963-970. doi: 10.1002/ejhf.3218. Epub 2024 Apr 4. Eur J Heart Fail. 2024. PMID: 38572654 Clinical Trial.
Rationale and design of the EMPERIAL-Preserved and EMPERIAL-Reduced trials of empagliflozin in patients with chronic heart failure.
Abraham WT, Ponikowski P, Brueckmann M, Zeller C, Macesic H, Peil B, Brun M, Ustyugova A, Jamal W, Salsali A, Lindenfeld J, Anker SD; EMPERIAL Investigators and National Coordinators. Abraham WT, et al. Among authors: brueckmann m. Eur J Heart Fail. 2019 Jul;21(7):932-942. doi: 10.1002/ejhf.1486. Epub 2019 Jun 19. Eur J Heart Fail. 2019. PMID: 31218819 Free PMC article.
Effects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKD.
Mayne KJ, Staplin N, Keane DF, Wanner C, Brenner S, Cejka V, Stegbauer J, Judge PK, Preiss D, Emberson J, Trinca D, Dayanandan R, Lee R, Nolan J, Omata A, Green JB, Cherney DZI, Hooi LS, Pontremoli R, Tuttle KR, Lees JS, Mark PB, Davies SJ, Hauske SJ, Steubl D, Brückmann M, Landray MJ, Baigent C, Haynes R, Herrington WG; EMPA-KIDNEY Collaborative Group. Mayne KJ, et al. J Am Soc Nephrol. 2024 Feb 1;35(2):202-215. doi: 10.1681/ASN.0000000000000271. Epub 2023 Dec 12. J Am Soc Nephrol. 2024. PMID: 38082486 Free PMC article. Clinical Trial.
Impact of empagliflozin on insulin needs in patients with heart failure and diabetes: An EMPEROR-Pooled analysis.
Talha KM, Green J, Filippatos G, Pocock S, Zannad F, Brueckmann M, Schueler E, Ofstad AP, Ferreira JP, Anker SD, Butler J, Rosenstock J, Packer M. Talha KM, et al. Among authors: brueckmann m. Diabetes Obes Metab. 2024 Jul;26(7):2578-2587. doi: 10.1111/dom.15572. Epub 2024 Apr 1. Diabetes Obes Metab. 2024. PMID: 38558314 Free article. Clinical Trial.
Body mass index and cardiorenal outcomes in the EMPEROR-Preserved trial: Principal findings and meta-analysis with the DELIVER trial.
Sattar N, Butler J, Lee MMY, Harrington J, Sharma A, Zannad F, Filippatos G, Verma S, Januzzi JL, Ferreira JP, Pocock SJ, Pfarr E, Ofstad AP, Brueckmann M, Packer M, Anker SD. Sattar N, et al. Among authors: brueckmann m. Eur J Heart Fail. 2024 Apr;26(4):900-909. doi: 10.1002/ejhf.3221. Epub 2024 Apr 1. Eur J Heart Fail. 2024. PMID: 38558521 Clinical Trial.
Time from admission to randomization and the effect of empagliflozin in acute heart failure: A post-hoc analysis from EMPULSE.
Ferreira JP, Blatchford JP, Teerlink JR, Kosiborod MN, Angermann CE, Biegus J, Collins SP, Tromp J, Nassif ME, Psotka MA, Comin-Colet J, Mentz RJ, Brueckmann M, Nordaby M, Ponikowski P, Voors AA. Ferreira JP, et al. Among authors: brueckmann m. Eur J Heart Fail. 2024 Sep;26(9):1976-1983. doi: 10.1002/ejhf.3369. Epub 2024 Jul 9. Eur J Heart Fail. 2024. PMID: 38980272 Clinical Trial.
Empagliflozin in acute myocardial infarction in patients with and without type 2 diabetes: A pre-specified analysis of the EMPACT-MI trial.
Petrie MC, Udell JA, Anker SD, Harrington J, Jones WS, Mattheus M, Gasior T, van der Meer P, Amir O, Bahit MC, Bauersachs J, Bayes-Genis A, Chopra VK, Januzzi JL, Lopes RD, Ponikowski P, Rossello X, Schou M, Zieroth S, Brueckmann M, Sumin M, Bhatt DL, Hernandez AF, Butler J. Petrie MC, et al. Among authors: brueckmann m. Eur J Heart Fail. 2024 Dec 26. doi: 10.1002/ejhf.3548. Online ahead of print. Eur J Heart Fail. 2024. PMID: 39725521
The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial.
Judge PK, Tuttle KR, Staplin N, Hauske SJ, Zhu D, Sardell R, Cronin L, Green JB, Agrawal N, Arimoto R, Mayne KJ, Sammons E, Brueckmann M, Shah SV, Rossing P, Nangaku M, Landray MJ, Wanner C, Baigent C, Haynes R, Herrington WG. Judge PK, et al. Among authors: brueckmann m. Nephrol Dial Transplant. 2024 Nov 12:gfae263. doi: 10.1093/ndt/gfae263. Online ahead of print. Nephrol Dial Transplant. 2024. PMID: 39533115
Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™-1 and -2).
Wharton S, le Roux CW, Kosiborod MN, Platz E, Brueckmann M, Jastreboff AM, Ajaz Hussain S, Pedersen SD, Borowska L, Unseld A, Kloer IM, Kaplan LM; SYNCHRONIZE‐1 and ‐2 trial committees and investigators. Wharton S, et al. Among authors: brueckmann m. Obesity (Silver Spring). 2025 Jan;33(1):67-77. doi: 10.1002/oby.24184. Epub 2024 Nov 4. Obesity (Silver Spring). 2025. PMID: 39495965 Free PMC article.
214 results